



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

27 May 2024
EMA/MB/229817/2024
Management Board

Decision of the Management Board

Amending budget No. 03, amending appropriations in budget 2024

THE MANAGEMENT BOARD,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council, and in particular Article 67(11) thereof,

Having regard to the Financial Regulation applying to the Agency, and in particular Articles 26, 33 and 34 thereof,

Having regard to the proposal of the Executive Director representing the Agency,

Having regard to the agreement reached between the Agency and WeWork on the continuation of the lease agreement that formed the basis for a Building dossier submitted and approved by the Budgetary Authority in April 2024,

Having regard to the approval by the budgetary authority on the European Medicines Agency's intention to amend its ongoing sub-underlease for the London premises located in 30 Churchill Place (building dossier),

Having regard to the new terms of sub-underlease agreement to be signed between EMA and WeWork UK which foresees a reduction of the rent that can be partially offset by a percentage of the turnover realised by WeWork UK,

Having regard that the contract negotiations and contract preparation are ongoing,

Having regard that rent payment to CW will need to be made for Q3 and Q4 within the timelines of head lease.

Having regard that EU amending budget may be adopted after Q4 payments to the Landlord have to be made,

Having regard to the agreement that the rent reduction should be covered by an increase of EU contribution,

Whereas any amendments to the budget, including the establishment plan, shall be subject to an amending budget adopted by the same procedure as the initial budget.



HAS DECIDED

Article 1

The Agency's general budget (fund source C1) for 2024 shall be amended as detailed in Annex I. The changes to the activity-based budget are outlined in Annex II. This amending budget does not affect the Annual programming for 2024.

Article 2

The Executive Director shall implement this decision.

Amsterdam, 12 June 2024

Lorraine Nolan (signature on file)
Chair of the Management Board

Annex I to EMA/MB/229817/2024

Item	Description	Outturn as per year-end accounts (provisional)	Appropriation as per adopted budget (incl. amending budgets & transfers implemented during the year)	Amending budget No. 3	Appropriations, adopted and amending budgets
		2023	2024	2024	2024
REVENUE					
Title 2 EUROPEAN UNION AND EEA CONTRIBUTIONS					
2000	European Union and EEA contribution	€ 14,421,263	€ 18,783,000	€ 2,286,000	€ 21,069,000
Title 9 MISCELLANEOUS REVENUE					
9000	Miscellaneous revenue	€ 225,152	€ 274,000	€ 1,939,000	€ 2,213,000
Total revenue				€ 4,225,000	
EXPENDITURE					
Title 2 Infrastructure & operating expenditure					
Chapter 20 Infrastructure & operating expenditure					
2000	Rent	€ 10,937,841	€ 19,160,000	€ 5,125,000	€ 24,285,000
2090	Utilities & other building charges	€ 1,319,000	€ 1,793,000	-€ 900,000	€ 893,000
Total expenditure				€ 4,225,000	

Annex II to EMA/MB/229817/2024

Activity Based Budget (ABB)

Work programme activities	STAFF		Staff expenditure	Infrastructure, IT and project exp.	Meeting exp. (incl. overhead)	Evaluation Service (NCAs)	Other operational expenditure	Total expenditure	
	Temporary Agent	Contract Agent & Seconded National Experts	Title 1	Title 2 & Budget Item 3105	Budget item 3000 & 3003	Article 301	Articles 302 & 303		
	FTEs	FTEs	C'000	C'000	C'000	C'000	C'000	C'000	%
1 Evaluation activities for human medicines	282	109	67,582	37,841	5,461	161,158	8,087	280,129	59%
1.1 Pre-authorisation activities	78	31	19,805	6,406	2,963	29,156	54	58,384	12%
1.2 Initial evaluation activities	50	13	11,180	3,284	30	18,275	1,050	33,818	7%
1.3 Post-authorisation activities	73	24	15,769	14,361	-	96,776	1,960	128,867	27%
1.4 Referrals	6	1	1,044	384	9	-	160	1,596	0%
1.5 Pharmacovigilance activities	45	23	11,343	10,186	1,616	16,950	4,470	44,565	9%
1.6 Other specialized areas and activities	25	15	7,401	2,253	843	-	7	10,504	2%
1.7 Medical Devices	4	1	1,040	967	-	-	387	2,394	1%
2 Evaluation activities for veterinary medicines	33	16	8,176	6,322	625	7,074	535	22,732	5%
2.1 Pre-authorisation activities	1	0	302	123	317	301	2	1,045	0%
2.2 Initial evaluation activities	9	2	1,678	526	25	1,368	263	3,859	1%
2.3 Post-authorisation activities	10	3	1,996	869	-	2,585	235	5,684	1%
2.4 Arbitrations and Referrals	1	1	238	95	-	-	7	340	0%
2.5 Pharmacovigilance activities	5	4	1,614	3,978	122	2,821	27	8,562	2%
2.6 Other specialized areas and activities	7	6	2,350	731	161	-	-	3,242	1%
3 Horizontal activities and other areas	212	92	53,925	42,954	10,026	6,544	19,933	133,381	28%
3.1 Committee coordination	53	27	13,432	8,652	5,231	-	2,000	29,316	6%
3.2 Inspection and Compliance	24	20	6,887	2,880	860	6,544	34	17,205	4%
3.3 Partners and Stakeholders	34	11	8,788	2,522	1,868	-	658	13,837	3%
3.3a Transparency and access to documents	15	9	4,071	1,401	-	-	-	5,472	1%
3.3b Information	37	16	9,091	7,532	991	-	119	17,734	4%
3.4 International activities	15	1	3,650	960	227	-	-	4,837	1%
3.5 Information Management (incl. EU Telematics)	34	9	8,005	19,005	848	-	17,122	44,981	9%
4 Corporate Governance and Support activities	139	32	28,796	13,004	431	-	8	42,239	9%
4.1 Governance, quality management and internal audit	24	5	6,233	2,360	431	-	-	9,023	2%
4.2 Finance	31	10	6,290	3,140	-	-	8	9,438	2%
4.3 Information technology	26	5	5,693	1,761	-	-	-	7,454	2%
4.4 Human resources	47	11	8,746	5,043	-	-	-	13,789	3%
4.5 Infrastructure services	11	1	1,834	701	-	-	-	2,535	1%
Total	666	248	158,479	100,121	16,543	174,776	28,563	478,482	100%

FTEs are calculated as follows:	FTEs
Temporary Agents	691
Less vacancy	25
Estimated Temporary Agents	666
Contract Agents	203
Seconded National Experts	45
Total Staff	914

Rent expenditure related to building located in 30 Churchill Place - London	13,125
Budget 2024	491,607